Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

BACKGROUND: Ofatumumab is approved for the treatment of relapsing multiple sclerosis (RMS). Ongoing safety reporting is crucial to understand its long-term benefit–risk profile. OBJECTIVE: Report the safety and tolerability of ofatumumab in RMS after extended treatment up to 3.5 years. METHODS: Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Stephen L, Cross, Anne H, Winthrop, Kevin, Wiendl, Heinz, Nicholas, Jacqueline, Meuth, Sven G, Giacomini, Paul S, Saccà, Francesco, Mancione, Linda, Zielman, Ronald, Bagger, Morten, Das Gupta, Ayan, Häring, Dieter A, Jehl, Valentine, Kieseier, Bernd C, Pingili, Ratnakar, Stoneman, Dee, Su, Wendy, Willi, Roman, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330270/
https://www.ncbi.nlm.nih.gov/pubmed/35229668
http://dx.doi.org/10.1177/13524585221079731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330270/
https://www.ncbi.nlm.nih.gov/pubmed/35229668
http://dx.doi.org/10.1177/13524585221079731

Ejemplares similares